Remove Dermatology Remove Hormones Remove Insulin Remove Medicine
article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

With each passing year, pharmaceutical companies around the globe strive to deliver cutting-edge medicines, therapies and vaccines that impact the lives of millions. In this in-depth article, we embark on a captivating journey to uncover the top 30 pharma and biotech companies that have been instrumental in shaping the future of medicine.

Sales 98
article thumbnail

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Padcev® (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

The Pharma Data

Immune-mediated adverse reactions can occur at any time during or after treatment with KEYTRUDA, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, dermatologic reactions, solid organ transplant rejection, and complications of allogeneic hematopoietic stem cell transplantation. Initiate hormone replacement as indicated.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bristol Myers Squibb Statement on Opdivo® (nivolumab) Monotherapy Post-Sorafenib Hepatocellular Carcinoma U.S. Indication

The Pharma Data

The goal of the company’s cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility. endocrinopathies and dermatologic reactions) are discussed below. Hypophysitis can cause hypopituitarism; initiate hormone replacement as clinically indicated.

article thumbnail

Bristol Myers Squibb Statement on Opdivo® (nivolumab) Hepatocellular Carcinoma U.S. Indication

The Pharma Data

The goal of the company’s cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility. endocrinopathies and dermatologic reactions) are discussed below. Hypophysitis can cause hypopituitarism; initiate hormone replacement as clinically indicated.

Trials 52